Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06537908
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-31
Brief Title:
Anti-PD-1PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase III Study of Anti-PD-1PD-L1 Antibodies Combined With Anti-VEGF Antibody Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being done to analyze the safety tolerability and efficacy of treatment using combination of anti-VEGF and anti-PD-1PDL1 antibodies for patients with advanced hepatocellular carcinoma
Detailed Description:
This is a study of combination anti-PD-1PD-L1 antibodies and anti-VEGF for adult patients 18 with advanced hepatocellular carcinoma
Anti-VEGF including Avastin IBI305 etc is designed to block a protein called vascular endothelial growth factor therefore blocking the blood supply that feeds the tumor Also Anti-VEGF has recently been shown to play a key role regulating cancer cell proliferation trough epigenetic pathway
Anti-PD-1PD-L1 antibodies including pembrolizumeb nivolumab sintilimab toripalimab camrelizumeb tislelizumab and atezolizumab etc are given intravenously at assigned dose Treatment may continue until disease progression intolerable toxicity or consent withdrawal
This study is aimed to evaluate the safety and efficacy of the combination of anti-VEGF and PD-1PD-L1 mAb in unresectable late-stage HCC patients
Anti-VEGF including Avastin IBI305 etc is designed to block a protein called vascular endothelial growth factor therefore blocking the blood supply that feeds the tumor Also Anti-VEGF has recently been shown to play a key role regulating cancer cell proliferation trough epigenetic pathway
Anti-PD-1PD-L1 antibodies including pembrolizumeb nivolumab sintilimab toripalimab camrelizumeb tislelizumab and atezolizumab etc are given intravenously at assigned dose Treatment may continue until disease progression intolerable toxicity or consent withdrawal
This study is aimed to evaluate the safety and efficacy of the combination of anti-VEGF and PD-1PD-L1 mAb in unresectable late-stage HCC patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None